Interaction Checker
Potential Interaction
Dolutegravir/Lamivudine (DTG/3TC)
Efavirenz (EFV)
Quality of Evidence: Very Low
Summary:
Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with efavirenz would be possible from a pharmacokinetic standpoint. The European product label for Dovato recommends an additional 50 mg tablet of dolutegravir should be administered, approximately 12 hours after Dovato, during coadministration with efavirenz. Coadministration of dolutegravir and efavirenz decreased dolutegravir AUC, Cmax and Cmin by 57%, 39% and 75%, respectively. There was no change in efavirenz when compared to historical controls. Coadministration of lamivudine (150 mg twice daily) with efavirenz (600 mg once daily) increased lamivudine Cmin by 265%, but had no effect on lamivudine Cmax or AUC. Switching from efavirenz to dolutegravir decreased dolutegravir Ctrough by 60% and 85% in CYP2B6 normal and slow/intermediate metabolizers, respectively. CYP2B6 slow metabolizers experienced more prolonged subtherapeutic dolutegravir concentrations. When switching from efavirenz to dolutegravir, consider administering dolutegravir 50 mg twice daily for 2 weeks (as an additional 50 mg tablet of dolutegravir administered approximately 12 hours after Dovato) in patients who are not virologically suppressed, or who have resistance to efavirenz, or in patients who are CYP2B6 slow metabolizers.
Description:
View all available interactions with Dolutegravir/Lamivudine (DTG/3TC) by clicking here.
Copyright © 2026 The University of Liverpool. All rights reserved.